ArticleJournal for immunotherapy of cancer2019

A novel anti-HER2 anthracycline-based antibody-drug conjugate induces adaptive anti-tumor immunity and potentiates PD-1 blockade in breast cancer.

Lucia D'Amico et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.